drugset / Trial / NCT05009927

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

NCT05009927 ↗

Phase 2 Recruiting 50 enrolled Centre Leon Berard
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease. In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.

Timeline

Start
2022-01-03
Primary completion
2025-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 300 mg —
Subject Imatinib Small molecule 400 mg —